Booth Gardner Parkinson’s Care Center is conducting a Phase 2, randomized, double-blind, placebo-controlled crossover study to evaluate the effect of an investigational drug, TAK-071, when compared to placebo on gait in participants with Parkinson’s Disease (PD) who also have cognitive impairment.
Who may be eligible to participate?
- Between 40 to 75 years of age
- Have been diagnosed with PD
- Has elevated risk for falls as indicated by at least 2 falls in the last 6 months before the screening visit
- Has a caregiver who spends a minimum of 2 hours a day with the subject
Other inclusion/exclusion criteria apply.
What does participation involve?
The total amount of time a subject may be involved in the study is up to 23 weeks, including one 6-week (or less) period to test eligibility, two 6-week periods of receiving TAK-071 (or placebo), a 3-week period in between during which a subject receives neither, and up to 2 weeks for a follow-up period.
There will be a total of 5 clinic visits, with the screening visit lasting approximately 2 hours and each other visit lasting approximately 4-5 hours. There will be 3 phone visits, and each call is expected to take less than 1 hour.
Investigator
Pinky Agarwal, MD, FAAN
